Effects of Emamectin Benzoate on Atlantic Salmon
Author Information
Author(s): Pål A. Olsvik, Kai K. Lie, Eva Mykkeltvedt, Ole B. Samuelsen, Kjell Petersen, Anne-Kristin Stavrum, Bjørn T. Lunestad
Primary Institution: National Institute of Nutrition and Seafood Research
Hypothesis
To examine the toxic effects and stress induction of emamectin benzoate in Atlantic salmon.
Conclusion
A standard seven-day treatment with emamectin benzoate has only modest effects on gene transcription in the liver of Atlantic salmon.
Supporting Evidence
- The highest concentrations of emamectin benzoate were found in liver tissue at day 14.
- Gene set enrichment analysis indicated oxidative stress and inflammation responses in treated fish.
- Transcription levels of HSP70 and GST were significantly increased in the liver of medicated fish at day 35.
Takeaway
The study looked at how a medicine for fish affects their bodies. It found that the medicine doesn't change much in the fish's genes.
Methodology
Juvenile Atlantic salmon were treated with emamectin benzoate and their liver, muscle, and skin tissues were analyzed for drug concentration and gene expression using microarray and qPCR.
Limitations
The study primarily focused on liver tissue and may not represent effects in other tissues or long-term impacts beyond 35 days.
Participant Demographics
Juvenile Atlantic salmon (Salmo salar L.)
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website